Psychosis, Neuroscience, Dopamine receptor D2, Schizophrenia and Antipsychotic are his primary areas of study. Shitij Kapur focuses mostly in the field of Psychosis, narrowing it down to topics relating to Dopamine and, in certain cases, Salience. His Dopamine receptor D2 study incorporates themes from Haloperidol, Risperidone, Clozapine and Pharmacology.
He works mostly in the field of Haloperidol, limiting it down to topics relating to Anesthesia and, in certain cases, Quetiapine. His research on Schizophrenia concerns the broader Psychiatry. His Olanzapine research extends to the thematically linked field of Antipsychotic.
His scientific interests lie mostly in Schizophrenia, Internal medicine, Psychiatry, Antipsychotic and Neuroscience. His Schizophrenia research integrates issues from Positron emission tomography, Psychosis, Cognition and Clinical psychology. His Internal medicine research is multidisciplinary, incorporating perspectives in Placebo, Endocrinology and Atypical antipsychotic.
His studies in Psychiatry integrate themes in fields like Randomized controlled trial and Clinical trial. The various areas that Shitij Kapur examines in his Antipsychotic study include Clozapine, Haloperidol, Olanzapine, Risperidone and Pharmacology. Dopamine covers Shitij Kapur research in Dopamine receptor D2.
Shitij Kapur focuses on Schizophrenia, Psychiatry, Psychosis, Internal medicine and Neuroscience. His work deals with themes such as Anterior cingulate cortex, Dopamine, Clinical psychology, Positron emission tomography and Depression, which intersect with Schizophrenia. His Psychosis study deals with Glutamate receptor intersecting with Neuroimaging.
His research in Internal medicine intersects with topics in Endocrinology, Placebo, Olanzapine, Antipsychotic and Positive and Negative Syndrome Scale. His research integrates issues of Haloperidol, Aripiprazole, Dopamine receptor D2, First episode and First episode psychosis in his study of Antipsychotic. His study on Basal ganglia is often connected to PDE10A as part of broader study in Neuroscience.
Shitij Kapur mostly deals with Schizophrenia, Internal medicine, Psychiatry, Psychosis and Neuroscience. His biological study spans a wide range of topics, including Major depressive disorder, Depression, Genetics and Clinical psychology. The study incorporates disciplines such as Antipsychotic, Placebo, Endocrinology and Positive and Negative Syndrome Scale in addition to Internal medicine.
His work carried out in the field of Psychiatry brings together such families of science as Placebo-controlled study, Clinical trial and Affect. His Psychosis research is multidisciplinary, incorporating elements of Jumping to conclusions, Cognitive bias, Distress, Case-control study and First episode. His research on Neuroscience often connects related areas such as Huntingtin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia.
American Journal of Psychiatry (2003)
The Dopamine Hypothesis of Schizophrenia: Version III—The Final Common Pathway
Oliver D. Howes;Shitij Kapur.
Schizophrenia Bulletin (2009)
Hemispheric encoding/retrieval asymmetry in episodic memory: positron emission tomography findings
Endel Tulving;Shitij Kapur;Fergus I. M. Craik;Morris Moscovitch.
Proceedings of the National Academy of Sciences of the United States of America (1994)
Grand challenges in global mental health
Pamela Y. Collins;Vikram Patel;Vikram Patel;Sarah S. Joestl;Dana March;Dana March.
Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Shitij Kapur;Philip Seeman.
American Journal of Psychiatry (2001)
Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia
Shitij Kapur;Robert Zipursky;Corey Jones;Gary Remington.
American Journal of Psychiatry (2000)
Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it
S Kapur;A G Phillips;T R Insel.
Molecular Psychiatry (2012)
The Maudsley Prescribing Guidelines in Psychiatry
David Taylor;Carol Paton;Shitij Kapur;South London.
Serotonin-dopamine interaction and its relevance to schizophrenia
Shitij Kapur;Gary Remington.
American Journal of Psychiatry (1996)
The nature of dopamine dysfunction in schizophrenia and what this means for treatment
Oliver D. Howes;Joseph Kambeitz;Euitae Kim;Daniel Stahl.
Archives of General Psychiatry (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: